Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial by Collet, Jean-Philippe et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical outcomes according to permanent discontinuation of
clopidogrel or placebo in the CHARISMA trial
Citation for published version:
Collet, J-P, Montalescot, G, Steg, PG, Steinhubl, SR, Fox, KAA, Hu, TF, Johnston, SC, Hamm, CW, Bhatt,
DL & Topol, EJ 2009, 'Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in
the CHARISMA trial' Archives of cardiovascular diseases, vol. 102, no. 6-7, pp. 485-96. DOI:
10.1016/j.acvd.2009.03.012
Digital Object Identifier (DOI):
10.1016/j.acvd.2009.03.012
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Archives of cardiovascular diseases
Publisher Rights Statement:
Available under Open Access
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
AC
C
d
C
I
d
1
drchives of Cardiovascular Disease (2009) 102, 485—496
LINICAL RESEARCH
linical outcomes according to permanent
iscontinuation of clopidogrel or placebo in the
HARISMA trial
mpact clinique de l’arrêt déﬁnitif du clopidogrel ou du placebo
ans l’étude CHARISMA
Jean-Philippe Colleta, Gilles Montalescota,∗,
Philippe Gabriel Stegb, Steven R. Steinhublc,
Keith A.A. Foxd, Ting Fei Hue,
S. Claiborne Johnstonf, Christian W. Hammg,
Deepak L. Bhatth, Eric J. Topol i
a Inserm unit 937, institut de cardiologie, hôpital Pitié-Salpêtrière, Assistance
publique—Hôpitaux de Paris, bureau 236, 47, boulevard de l’Hôpital, 75013 Paris, France
b Inserm U698, université Paris-7, Assistance publique—Hôpitaux de Paris, Paris, France
c Gill Heart Institute, University of Kentucky, Lexington, KY, USA
d Cardiovascular Research, Division of Medical and Radiological Sciences, University of
Edinburgh, Edinburgh, Scotland
e Cleveland Clinic, Cleveland, OH, USA
f University of California, San Francisco, CA, USA
g Kerchoff Heart Center, Bad Nauheim, Germany
h VA Boston Healthcare System, Brigham and Women’s Hospital, Boston, MA, USA
i The Scripps Research Institute, Scripps Clinic, La Jolla, CA, USA
Received 25 January 2009; accepted 2 March 2009
Available online 11 June 2009
KEYWORDS
Acute coronary
syndrome;
Summary
Background.— Late discontinuation of clopidogrel after an acute coronary syndrome or stent
placement may be associated with a clinical rebound effect.Clopidogrel;
Rebound;
Atherothrombosis
Aims.— To describe the characteristics and evolution of patients non-compliant to study drug
in the prospective, randomized, double-blind CHARISMA trial.
Methods.— Of 15,603 patients aged 45 or older years with established atherothrombotic dis-
ease (coronary artery disease, stroke, peripheral arterial disease) or multiple cardiovascular
∗ Corresponding author. Fax: +33 1 42 16 29 31.
E-mail address: gilles.montalescot@psl.aphp.fr (G. Montalescot).
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MOTS CLÉS
Syndrome coronaire
aigu ;
Antiagrégant
plaquettaire ;
Athérome ;
Infarctus du
myocarde ;
Accident vasculaire
cérébral ;
Plaquette ;
InterruptionJ.-P. Collet et al.
risk factors, 2999 permanently interrupted (withdrawers) study drug (clopidogrel or placebo)
during follow-up. The primary endpoint was ﬁrst occurrence since randomization of myocardial
infarction, stroke or cardiovascular death.
Results.— Withdrawers displayed a higher risk proﬁle and rates of death/myocardial infarc-
tion/stroke (13.5% versus 5.6%; hazard ratio [HR]: 3.18; 95% conﬁdence interval [CI]:
3.05—3.32; p < 0.001) and severe bleeding (4.9% versus 0.7%; odds ratio [OR]: 7.42; 95% CI:
5.67—9.70; p < 0.001) versus non-withdrawers. Death/myocardial infarction/stroke occurred
after an average of 228 days (95%CI: 197—258) and was less frequent in patients assigned
to clopidogrel versus placebo (9.7% versus 11.9%; HR: 0.80; 95%CI: 0.64—1.00; p = 0.051);
the rate of severe bleeding was the same (4.0% versus 4.3%; OR: 0.92; 95%CI: 0.65—1.32;
p = 0.66). Among withdrawers, initial clopidogrel treatment was an independent correlate
of survival (HR: 0.74, 95%CI: 0.59—0.93; p = 0.011), but not severe bleeding (OR: 0.94;
95% CI: 0.65—1.35; p = 0.74). Kaplan-Meier curves for the primary endpoint suggested no
rebound effect or disease reactivation after discontinuation of clopidogrel compared with
placebo.
Conclusions.— Patients who stopped medication had increased rates of ischaemic and bleed-
ing events and mortality. Patients initially on clopidogrel had fewer ischaemic events than
those on placebo; discontinuation was not associated with any clinically detectable rebound
effect.
© 2009 Published by Elsevier Masson SAS.
Résumé
Contexte.— L’arrêt du clopidogrel chez des patients stables dans les suites d’un syndrome
coronaire aigu ou dans les suites d’une angioplastie avec stent peut être associé à un rebond
d’événement cardiovasculaire.
Objectifs.— Décrire les caractéristiques et l’évolution clinique des patients ayant arrêté le
traitement à l’étude dans l’essai CHARISMA.
Méthode.— Parmi les 15 603 patients âgés de plus de 45 ans et ayant une maladie athérothrom-
botique symptomatique (maladie coronaire, accident vasculaire cérébral, artérite des
membres inférieurs) ou à haut risque cardiovasculaire, 2999 ont interrompu déﬁnitive-
ment le traitement à l’étude (clopidogrel ou placebo) durant le suivi. Le critère primaire
de jugement était l’apparition d’un premier événement cardiovasculaire associant infarc-
tus du myocarde ou accident vasculaire cérébral ou décès cardiovasculaire à partir de
l’interruption.
Résultats.— Les patients ayant interrompu le traitement à l’étude (clopidogrel ou placebo)
avaient un proﬁl de risque plus sévère et ont présenté davantage d’événements cli-
niques ischémiques déﬁnis selon le critère combine décès/IDM/AVC (13,5 % versus 5,6 % ; HR :
3,18 ; 95 %CI : 3,05—3,32 ; p < 0,001) mais également davantage d’hémorragies sévères (4,9 %
versus 0,7 % ; OR : 7,42 ; 95 %CI : 5,67—9,70 ; p < 0,001) que les patients n’ayant pas inter-
rompu. L’incidence du critère combiné décès/IDM/AVC est survenu dans un délai moyen de
228 jours (95 %CI : 197—258) après l’arrêt et était moins fréquente chez les patients rece-
vant du clopidogrel que chez ceux ayant rec¸u du placebo (9,7 % versus 11,9 % ; HR : 0,80 ;
95 %CI : 0,64—1,00 ; p = 0,051), alors que le taux d’hémorragie sévère était similaire dans
les deux groupes (4,0 % versus 4,3 % ; OR : 0,92 ; 95 %CI : 0,65—1,32 ; p = 0,66). Parmi les
patients ayant arrêté le traitement à l’étude, le traitement initial par clopidogrel avant
interruption était un facteur prédictif indépendant de survie (HR : 0,74 ; 95 %CI : 0,59—0,93 ;
p = 0,011) mais pas de complications hémorragiques majeures (OR : 0,94 ; 95 %CI : 0,65—1,35 ;
p = 0,74). Les courbes de Kaplan-Meier pour le critère primaire de jugement ne suggèrent
pas d’effet rebond ou de réactivation de la maladie après l’arrêt du clopidogrel comparé au
placebo.
Conclusion.— Les patients qui ont arrêté le traitement à l’étude dans l’essai CHARISMA sont
caractérisés par une augmentation du risque de survenue d’événements ischémiques et hémor-
ragiques majeurs mais aussi de décès. Les patients initialement randomisés dans le groupe
clopidogrel ont eu moins de complications ischémiques que ceux sous placebo et l’arrêt du
traitement à l’étude n’était pas associé à un effet clinique rebond.
© 2009 Publie´ par Elsevier Masson SAS.
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Abbreviations
ACS acute coronary syndrome
CHARISMA clopidogrel for high atherothrombotic risk and
ischemic stabilization, management, and avoid-
ance
CI conﬁdence interval
DES drug-eluting stents
GUSTO global utilization of streptokinase and tissue plas-
minogen activator for occluded coronary arteries
HR hazard ratio
Background
Discontinuation of antiplatelet therapy in patients with
established atherothrombosis has become an increasingly
important concern. This is primarily because of the large
numbers of patients receiving dual oral antiplatelet ther-
apy after evidence accrued that clopidogrel on top of
aspirin provides an additional beneﬁt compared with aspirin
alone in ACS and/or after intracoronary stent placement
[1—5]. The other reason is that discontinuation of any oral
antiplatelet agent appears to be detrimental. Aspirin discon-
tinuation in patients with stable coronary artery disease who
are treated with aspirin alone is associated with an increased
risk of death [6,7]. The risk of antiplatelet treatment with-
drawal is even higher in stented patients, especially when
DES have been used [8—13].
Dual oral antiplatelet therapy is now recommended for
at least 1 year in patients with a recent ACS or intracoro-
nary DES placement [14]. However, an additional concern
is whether discontinuation of clopidogrel late after the
acute event in stabilized patients who remain on aspirin
is associated with a related hazard. Indeed, premature
discontinuation of clopidogrel in patients who underwent
intracoronary DES placement is associated with increased
mortality in patients despite continuation of aspirin [15].
Whether late discontinuation of clopidogrel, months or years
after an ACS or a stent placement or in patients with estab-
lished atherothrombotic disease, is associated with a clinical
rebound effect is unknown.
In the CHARISMA trial, the combination of clopidogrel
plus aspirin did not provide a signiﬁcantly greater protec-
tion against cardiovascular events than aspirin alone in a
broad population of patients with either cardiovascular risk
factors or established atherothrombotic disease, although a
signiﬁcant beneﬁt was observed with dual antiplatelet treat-
ment in patients with established atherothrombotic disease
[16]. In the present report, we analysed the baseline char-
acteristics and clinical outcomes of patients randomized
in the CHARISMA trial who permanently discontinued the
study drug (clopidogrel or placebo) while continuing aspirin
therapy. We hypothesized that these patients who interrupt
study drug would be at higher risk and may suffer from a
rebound effect after clopidogrel cessation.
MethodsDesign
The CHARISMA trial was a prospective, multicentre, ran-
domized, double-blind, placebo-controlled study of the
b
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fﬁcacy and safety of clopidogrel plus aspirin compared
ith aspirin alone in patients at high risk for a cardiovas-
ular event [16]. Brieﬂy, patients were eligible for the trial
f they were 45 years of age or older and had established
therothrombotic disease (i.e., coronary artery disease,
troke or peripheral arterial disease) or if they had mul-
iple cardiovascular risk factors and had not yet sustained
n ischaemic event. Patients were excluded if, in the judg-
ent of the investigator, they had established indications for
lopidogrel therapy (such as a recent ACS or stent implanta-
ion). Patients scheduled to undergo revascularization were
ot allowed to enroll until the procedure had been com-
leted.
eﬁnition of discontinuation
nly patients who permanently discontinued the study drug
clopidogrel or placebo) were considered in the present
nalysis. Reasons for discontinuation included adverse
vents, moderate or severe bleeding, subject’s request,
ualifying condition absent or any other reason. Patients
ho interrupted temporarily (<2weeks) were not considered
n this analysis.
ndpoints
he primary endpoint was the same as that used in the
HARISMA study, that is, ﬁrst occurrence since random-
zation of myocardial infarction, stroke (of any cause) or
ardiovascular death (including haemorrhage). We also con-
idered cardiovascular death as a coprimary endpoint in the
resent analysis, given the evidence that withdrawal of an
ral antiplatelet agent has been associated with a signiﬁcant
ncrease in mortality [6,7].
As in the main analysis from the overall trial, the pri-
ary safety endpoint was severe bleeding, according to
he GUSTO deﬁnition, which includes fatal bleeding and
ntracranial haemorrhage or bleeding that causes haemo-
ynamic compromise requiring blood or ﬂuid replacement,
notropic support or surgical intervention.
tatistical analysis
ata were analysed on an intention-to-treat basis, with the
nclusion of all patients according to their randomly assigned
reatment group and the inclusion of outcomes occurring
rom randomization to a common study end date (29 August
005). The time to ﬁrst occurrence of any event in the
omposite cluster was used for analysis. Data in patients who
id not reach the primary endpoint by the study end date
ere censored on the date of the patient’s last assessment
isit. Death from non-cardiovascular causes was treated as
competing event and follow-up was censored on the date
f death.
The primary efﬁcacy endpoint of withdrawers compared
ith non-withdrawers was assessed using a two-sided log-
ank test. The treatment discontinuation effect as measured
y the HR and its associated 95% CI was estimated using the
ox proportional-hazards model by using time to event from
andomization. Cumulative Kaplan-Meier estimates of the
vent rates from randomization were also calculated to test
he clinical outcomes according to study drug discontinua-
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Table 1 Baseline characteristics of patients who permanently discontinued the study drug (clopidogrel or placebo)
versus non-withdrawers.
No discontinuation
(n = 12,604)
Discontinuation
(n = 2999)
p
Demographic
Age (years) 64 (56—71) 67 (59—74) <0.001
≥75 years 1872 (14.9) 651 (21.7) <0.001
Women 3632 (28.8) 1012 (33.7) <0.001
Body mass index 28.6 ± 5.20 28.7 ± 5.35 0.58
Selected clinical characteristics
Current smoker 2539 (20.1) 616 (20.5) 0.63
Hypertension 9172 (72.8) 2311 (77.1) <0.001
Hypercholesterolaemia 9327 (74.0) 2208 (73.6) 0.67
Congestive heart failure 696 (5.5) 230 (7.7) <0.001
Prior myocardial infarction 4385 (34.8) 1012 (33.7) 0.28
Atrial ﬁbrillation 418 (3.3) 165 (5.5) <0.001
Diabetes 5271 (41.8) 1285 (42.8) 0.31
Peripheral artery disease 2778 (22.0) 753 (25.1) <0.001
Prior percutaneous coronary intervention 2868 (22.8) 686 (22.9) 0.89
Prior CABG 2441 (19.4) 638 (21.3) 0.018
Prior stroke 3119 (24.7) 718 (23.9) 0.36
Prior transient ischaemic attack 1431 (11.4) 433 (14.4) <0.001
Prior carotid endarterectomy 658 (5.2) 167 (5.6) 0.44
Prior peripheral angioplasty or bypass 1356 (10.8) 381 (12.7) 0.002
Diabetic nephropathy 1591 (12.6) 418 (13.9) 0.053
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vValues are n (%), median (range) or mean± S.D.; CABG: coronary
ion. Cumulative incidence event curves were calculated to
nvestigate the rebound effect or disease reactivation after
lopidogrel interruption in comparison to placebo interrup-
ion by using time from drug discontinuation to the ﬁrst
rimary clinical outcome. Statistical comparisons of the pri-
ary safety event rates in the two groups were performed
sing Pearson’s 2 test. A multivariable time-dependent Cox
odel for the overall population was performed to iden-
ify independent correlates of mortality. A multivariable
ogistic model was also performed to assess whether perma-
ent discontinuation was an independent correlate of severe
leeding. All analyses were performed with SAS software
version 8.0, SAS Institute).
esults
aseline characteristics
mong the 15,603 patients enrolled in the CHARISMA trial,
999 permanently interrupted the study drug (clopidogrel
r placebo) during follow-up. The baseline characteristics
f these patients are listed in Table 1. Patients who perma-
ently interrupted the study drug had a higher risk proﬁle
ompared with those who did not. They were older and
ere more frequently women. They also presented more
ascular comorbidities, along with congestive heart failure
nd atrial ﬁbrillation (Table 1). The major reason for dis-
ontinuation was subjects’ request (n = 1299, 43.3%); the
ther reasons were occurrence of an adverse event (n = 748,
4.9%), severe or moderate bleeding (n = 181, 6.0%), qual-
S
n
T
r
ty bypass graft.
fying condition absent (n = 66, 2.2%) and any other reason
n = 705, 23.5%; Table 2). The average delay from randomiza-
ion to discontinuation was 287 days (95% CI 277—296) and
as longer in patients allocated to clopidogrel (306 days;
5% CI 295—318) compared with those allocated to placebo
269 days; 95% CI 259—279; p < 0.001). Time from random-
zation to discontinuation represented 27.8% of the whole
ollow-up duration.
Among withdrawers, there was no difference in baseline
haracteristics between patients who interrupted clopido-
rel and those who interrupted placebo (Table 3). Treatment
as permanently discontinued by 20.4% of patients in the
lopidogrel group compared with 18.2% in the placebo group
p < 0.001) over the whole study period (up to 4 years). A
otal of 4.8% of the patients in the clopidogrel group and
.9% of those in the placebo group discontinued treatment
ecause of an adverse event (p = 0.67; Table 2). Discontinua-
ion for moderate or severe bleeding was twice as frequent
n the clopidogrel group as in the control group; 99.7% of
atients were compliant to aspirin during the entire study
ollow-up.
linical outcomes according to discontinuation
ersus continuation of study drugtudy-drug withdrawers had worse clinical outcomes than
on-withdrawers. The ischaemic endpoints are shown in
able 4. With a median of 28months of follow-up, the
ate of the primary endpoint was increased more than
wofold in the withdrawer group (versus non-withdrawers).
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Table 2 Reasons for permanent discontinuation of the study drug (clopidogrel or placebo).
Placebo + aspirin
(n = 1415)
Clopidogrel + aspirin
(n = 1584)
p
Subject’s request 627 (44.3) 672 (42.4) 0.001 (overall 2
test)Adverse event 380 (26.9) 368 (23.2)
Other reason 319 (22.5) 386 (24.4)
Qualifying condition absent 33 (2.3) 33 (2.1)
Moderate or severe bleeding 56 (4.0) 125 (7.9)
d
i
w
s
f
(
s
p
(
b
t
pValues are n (%).
Each component of the primary endpoint was increased in
withdrawers versus non-withdrawers; in particular, the car-
diovascular mortality rate was 5.1% versus 2.5% respectively
(p < 0.001). These differences were present irrespective of
the type of patients (symptomatic versus asymptomatic) and
of the reasons for interruption (cessation after an event
versus consent withdrawal) (data not shown).
Using a time-dependent multivariable Cox model for
the overall population, permanent discontinuation of the
study drug was the most powerful independent correlate
of cardiovascular mortality (HR: 4.32, 95%CI: 3.66—5.09;
p < 0.001) along with age, heart failure, previous myocardial
infarction, peripheral arterial disease and stroke, whereas
concomitant therapy with statin, aspirin and nonsteroidal
anti-inﬂammatory drugs were independently associated
with survival (Fig. 1).
Kaplan-Meier curves from randomization to the ﬁrst
event of the primary efﬁcacy endpoint comparing with-
n
H
d
c
t
Table 3 Baseline characteristics of patients who permanently
Placebo
(n = 1
Demographic
Age (years) 66 (59—7
≥75 years 316 (22.3
Women 461 (32.6
Body mass index 28.6 ±
Selected clinical characteristics
Current smoker 301 (21.3
Hypertension 1096 (77
Hypercholesterolaemia 1055 (74
Congestive heart failure 102 (7.2)
Prior myocardial infarction 490 (34.6
Atrial ﬁbrillation 80 (5.7)
Diabetes 585 (41.3
Peripheral artery disease 365 (25.8
Prior percutaneous coronary intervention 326 (23.0
Prior CABG 308 (21.8
Prior stroke 350 (24.7
Prior transient ischaemic attack 200 (14.1
Prior carotid endarterectomy 75 (5.3)
Prior peripheral angioplasty or bypass 189 (13.4
Diabetic nephropathy 184 (13.0
Values are n (%), median (range) or mean± S.D.; CABG: coronary arterrawers with non-withdrawers showed an increase in the
ncidence of the primary efﬁcacy endpoint (p < 0.001) in
ithdrawers compared with most patients who remained on
tudy drug throughout follow-up (Fig. 2A). The average time
rom drug discontinuation to primary endpoint was 228 days
95% CI: 197—258), suggesting no immediate causal relation-
hip.
The difference in safety was even more dramatic in
atients who interrupted permanently the study drug
Table 4). The rate of the primary safety endpoint (severe
leeding) was 4.9% in the withdrawer group and 0.7% in
he non-withdrawer group (OR: 7.42; 95% CI: 5.67—9.70;
< 0.001). Of note, the rate of fatal bleeding increased
inefold in withdrawers compared with non-withdrawers.
owever, when considering patients who stopped the study
rug without obvious medical reason or adverse event (i.e.,
essation for consent withdrawal or on subject’s request),
he primary safety endpoint was similar in both groups
discontinued the study drug (clopidogrel or placebo).
+ aspirin
415)
Clopidogrel +
aspirin (n = 1584)
p
4) 66 (59—73) 0.76
) 335 (21.1) 0.67
) 551 (34.8) 0.21
5.34 28.8 ± 5.35 0.27
) 315 (19.9) 0.35
.5) 1215 (76.7) 0.63
.6) 1153 (72.8) 0.27
128 (8.1) 0.37
) 522 (33.0) 0.33
85 (5.4) 0.73
) 700 (44.2) 0.12
) 388 (24.5) 0.41
) 360 (22.7) 0.84
) 330 (20.8) 0.53
) 368 (23.2) 0.34
) 233 (14.7) 0.66
92 (5.8) 0.55
) 192 (12.1) 0.31
) 234 (14.8) 0.16
y bypass graft.
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Table 4 Composite and individual primary and secondary endpoints from randomization to end of follow-up in patients
who permanently discontinued the study drug.
Endpoint, n (%) No discontinuation
(n = 12,604)
Discontinuation
(n = 2999)
Hazard ratioa (95% CI) p
Primary efﬁcacy endpoint 702
(5.6)
405
(13.5)
3.18 (3.05—3.32) <0.001
CV death/MI/stroke 1838
(14.6)
858
(28.6)
2.42 (2.32—2.51) <0.001
Death 424
(3.4)
321
(10.7)
5.23 (5.08—5.38) <0.001
Cardiovascular death 313
(2.5)
154
(5.1)
3.53 (3.33—3.73)) <0.001
Non-cardiac death 111
(0.9)
167
(5.6)
9.6 1 (9.36—9.85) <0.001
Myocardial infarction 241
(1.9)
145
(4.8)
3.04 (2.82—3.27) <0.001
Stroke 260
(2.1)
181
(6.0)
23.31 (3.10—3.52) <0.001
Hospitalization 1277
(10.1)
546
(18.2)
1.96 (1.84—2.08) <0.001
Safety endpoint Odds ratio (95% CI)
Any bleed 3167 (25.1) 1276 (42.5) 2.21 (2.03—2.40) <0.001
Fatal bleed 15 (0.1) 28 (0.9) 7.91 (4.22—14.83) <0.001
Moderate bleed 114 (0.9) 151 (5.0) 5.81 (4.54—7.43) <0.001
Severe bleed 87 (0.7) 147 (4.9) 7.42 (5.67—9.70) <0.001
Symptomatic ICH 24 (0.2) 59 (2.0) 10.52 (6.53—16.94) <0.001
Minor bleed 3044 (24.2) 1089/2999 (36.3) 1.67 (1.55—1.78) <0.001
CI: conﬁdence interval; CV: cardiovascular; ICH: intracranial haemorrhage; MI: myocardial infarction.
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da Hazard ratios calculate by time-dependent Cox model.
1.5% versus 1.5%). Using a multivariable logistic model,
ermanent discontinuation of the study drug was found to
e an independent correlate of severe bleeding occurring
uring the whole follow-up (OR: 6.08, 95%CI: 4.62—8.01;
< 0.001). Kaplan-Meier curves from randomization to the
rst event of the primary safety endpoint showed an
ncrease in the incidence of the severe bleeding (p < 0.001)
n the withdrawers compared to the majority of patients
ho remained on study drug (Fig. 2B).
linical outcomes according to cessation of
lopidogrel or placebon patients in whom the study drug was withdrawn, the rate
f the primary endpoint from randomization remained sig-
iﬁcantly lower in patients allocated to previous therapy
ith clopidogrel compared with those allocated to placebo
Table 5). Total mortality was also signiﬁcantly lower in the
c
e
i
ilopidogrel group compared with the placebo group, as well
s the rate of stroke, while there was no difference in the
ate of recurrent myocardial infarction. Results were similar
fter deletion of events that had occurred before discontin-
ation and which represented ∼20% of the total number of
vents (Table 5), although the rate of the primary endpoint
as no longer signiﬁcantly lower in patients allocated to
revious therapy with clopidogrel compared with those allo-
ated to placebo (Table 5). Using a multivariable Cox model
n this population of withdrawers, clopidogrel was indepen-
ently correlated with survival (HR: 0.74; 95% CI: 0.60—0.95;
= 0.011) along with statin therapy, whereas age and prior
eart failure were among the most powerful correlates for
eath (Fig. 3).Kaplan-Meier curves starting at the time of study drug dis-
ontinuation showed an initial sharp decrease in the primary
ndpoint survival curves in both groups and ﬁnally fewer
schaemic events occurred in patients on clopidogrel than
n those on placebo (9.7% versus 11.9%; HR: 0.80; 95% CI:
Clinicaloutcom
es:
Perm
anent
discontinuation
of
clopidogrelin
the
CH
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Table 5 Composite and individual primary and secondary endpoints from both randomization and discontinuation to end of follow-up in patients who interrupted
placebo versus clopidogrel.
Endpoint Before and after discontinuation After discontinuation
Efﬁcacy
endpoint
Placebo
(n = 1415)
Clopidogrel
(n = 1584)
Hazard ratio
(95% CI)
p Placebo
(n = 1415)
Clopidogrel
(n = 1584)
Hazard ratio
(95% CI)
p
Primary efﬁcacy
endpoint
211 (14.9) 194 (12.2) 0.81 (0.67—0.98) 0.034 163 (11.9) 150 (9.7) 0.80 (0.64—1.00) 0.051
CV
death/MI/stroke/
hospitalization
447 (31.6) 411 (25.9) 0.79 (0.69—0.90) <0.001 283 (22.6) 286 (19.6) 0.84 (0.69—0.90) 0.045
Death 173 (12.2) 148 (9.3) 0.76 (0.61—0.94) 0.012 173 (12.2) 148 (9.3) 0.72 (0.58—0.90) 0.004
Cardiovascular
death
83 (5.9) 71 (4.5) 0.76 (0.55—1.04) 0.083 83 (5.9) 71 (4.5) 0.72 (0.52—0.99) 0.043
Non-cardiac
death
90 (6.4) 77 (4.9) 0.76 (0.56—1.02) 0.071 90 (6.4) 77 (4.9) 0.72 (0.53—0.98) 0.038
Myocardial
infarction
69 (4.9) 76 (4.8) 0.98 (0.71—1.36) 0.90 49 (3.5) 59 (3.8) 1.07 (0.73—1.56) 0.73
Stroke 98 (6.9) 83 (5.2) 0.75 (0.56—1.0) 0.048 70 (5.0) 56 (3.6) 0.70 (0.49—1.00) 0.049
Hospitalization 284 (20.1) 262 (16.5) 0.79 (0.67—0.94) 0.007 160 (12.4) 177 (11.8) 0.94 (0.76—1.16) 0.60
Safety endpoints Odds ratio (95% CI) Odds ratio (95% CI)
Any bleed 461 (32.6) 815 (51.5) 2.19 (1.89—2.54) <0.001 229 (19.4) 290 (27.4) 1.57 (1.29—1.91) <0.001
Fatal bleed 13 (0.9) 15 (0.9) 1.03 (0.49—2.17) 0.94 13 (0.9) 15 (0.9) 1.03 (0.49—2.17) 0.94
Severe bleed 69 (4.9) 78 (4.9) 1.01 (0.72—1.41) 0.95 61 (4.3) 63 (4.0) 0.92 (0.65—1.32) 0.70
Moderate bleed 54 (3.8) 97 (6.1) 1.64 (1.17—2.31) 0.004 46 (3.3) 75 (4.8) 1.49 (1.03—2.17) 0.035
Symptomatic ICH 29 (2.0) 30 (1.9) 0.92 (0.55—1.55) 0.76 25 (1.8) 25 (1.6) 0.89 (0.51—1.56) 0.69
CI: conﬁdence interval; CV: cardiovascular; ICH: intracranial haemorrhage; MI: myocardial infarction.
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.64—1.00; p = 0.051), with no suggestion of rebound or dis-
ase reactivation after clopidogrel interruption compared
o placebo discontinuation (Fig. 4A). Similar Kaplan-Meier
urves were found for mortality (data not shown).
Regarding severe bleeding, there was a sharp initial
ecrease in survival curves of both groups and ﬁnally there
as no difference in severe bleeding rates between patients
iscontinuing clopidogrel or placebo (Table 5 and Fig. 4B).
ost of the signiﬁcant bleeding events, including moder-
te and severe bleeds, occurred after discontinuation of
he study drug. Kaplan-Meier curves from the time of study-
rug discontinuation to the ﬁrst event of the primary safety
ndpoint showed no difference between patients receiving
lopidogrel compared with those on placebo (4.0% versus
.3%; OR: 0.92; 95% CI: 0.65—1.32; p = 0.67) (Fig. 4B). Time
elays of severe bleeding according to randomization or drug
iscontinuation were similar when considering discontinu-
tion of clopidogrel or placebo. In multivariable analysis,
lopidogrel discontinuation was not independently corre-
ated to severe bleeding (OR: 0.94; 95% CI: 0.65—1.35;
= 0.74).
iscussionhe present work shows that permanent discontinuation of
he study drug (clopidogrel or placebo) occurs in a substan-
ial proportion (19.3%) of the study population, which is
onsistent with previous reports on drug interruption in clini-
a
f
r
o
cl population.
al trials and with data on compliance to treatment [17—19].
n important ﬁnding is that discontinuation of study drug
dentiﬁes a very high-risk group of patients exposed to
ore frequent ischaemic events, increased mortality and
lso more frequent severe bleeding when considering events
ccurring during the whole follow-up. In the subgroup that
iscontinued the study drug and after deleting events that
ccurred before discontinuation, initial allocation to clopi-
ogrel was associated with a trend for fewer ischaemic
vents and was independently correlated with survival,
ithout the suggestion of any clinical rebound in this popu-
ation with stabilized atherothrombosis.
Thienopyridine therapy in combination with low-dose
spirin has become the mainstay antiplatelet treatment in
CS for up to 1 year irrespective of clinical presentation or
oronary revascularization procedures [2—4,14]. Consistent
nalyses have shown that the beneﬁts emerge rapidly after
he ﬁrst oral administration of clopidogrel [1,3,4] and data
eyond 30 days suggest further incremental beneﬁts [20].
hether the absolute difference continues to widen signif-
cantly beyond 3months is still debated, but there may be
potential hazard of premature clopidogrel discontinuation
ithin the ﬁrst year of follow-up [10,21,22].
The hazard related to discontinuation of antiplateletgents depends upon many factors. The most critical
actor is stent implantation [23], with mortality rates
anging from 5 to 15% when interruption of both agents
ccurs early after implantation [9,24]. Discontinuation of
lopidogrel within the ﬁrst month following implantation of
Clinical outcomes: Permanent discontinuation of clopidogrel in t
Figure 2. Kaplan-Meier survival curves from randomization to
ﬁrst event for (A) the primary efﬁcacy endpoint and (B) the primary
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usafety endpoint, comparing patients who discontinued the study
drug with non-withdrawers (log-rank test, p < 0.001 for both efﬁ-
cacy and safety endpoints). Events that occurred before and after
discontinuation have been considered.
a DES is associated with a marked increase of early stent
thrombosis and cardiovascular death [15]. Late interruption
of clopidogrel also remains a concern with DES, although
conﬂicting information has been published [8,10,25—27].
Extending beyond ACS and DES, the randomized CHARISMA
study provides a unique opportunity to assess the impact
of clopidogrel discontinuation in stable atherothrombotic
patients, whether symptomatic or not.
Patients with a recent ACS or a DES implantation or any
other condition in which clopidogrel treatment was required
were not enrolled in CHARISMA. The present analysis shows
that patients interrupting therapy (clopidogrel or placebo)
are at particular high risk of further ischaemic events and
death [7,19]. All kinds of events were increased among
withdrawers (versus non-withdrawers). The excess of risk
in withdrawers may be explained by more serious demo-
graphic characteristics and they were also more likely to
have preexisting established atherothrombotic disease. In
addition, a substantial proportion of withdrawers experi-
enced an adverse event during follow-up, which may have
sometimes, rightly or not, motivated discontinuation. All of
these characteristics in withdrawers depict a subgroup at
h
o
m
m
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articular high risk, in addition to the possibility of more
requent poor compliance to other treatments in this group.
onsent withdrawal was the principal reason for study drug
nterruption and this may be seen as an indicator of poor
ompliance.
Previous randomized double-blind trials have shown that
rug discontinuation is associated with worse outcomes irre-
pective of assignment to active drug or placebo [18]. In the
resent analysis, patients on clopidogrel had slightly better
utcomes than patients on placebo after discontinuation,
lthough there was no effect on the occurrence of myocar-
ial infarction. Some ‘‘carryover’’ effect and the high risk
roﬁle of withdrawers may account in part for this ﬁnding,
o that patients keep having a beneﬁt from prior exposure
o an active drug treatment even with a limited, although
ufﬁciently long, period of exposure (286 days on average).
n a similar manner to the results in the subgroup of non-
ithdrawers, other high-risk subsets of the CHARISMA study
opulation drew a signiﬁcant beneﬁt from dual antiplatelet
herapy (e.g., symptomatic patients, CAPRIE-like patients
28]), whereas this treatment strategy was not effective
n the main analysis [29]. Our results also indicate that
here was no detectable clinical rebound or reactivation
f atherothrombotic disease after withdrawal. Kaplan-Meier
urves (clopidogrel versus placebo) from the time of study
rug discontinuation to the ﬁrst event tended to be paral-
el over time, suggesting a sustained beneﬁt of clopidogrel
fter discontinuation without any rebound effect. It is likely
hat chronic aspirin treatment in these stable patients may
ave offered sufﬁcient protection after clopidogrel with-
rawal in the majority of cases. This is a major distinction
rom patients presenting with ACS and/or undergoing DES
lacement, who may have persistent platelet activation,
ncontrolled by aspirin, with a rebound of thrombotic events
fter clopidogrel discontinuation, as is now reported in sev-
ral studies [10,22].
Finally, this study shows an impressive relation between
iscontinuation and mortality, which doubled in withdrawers
ompared with non-withdrawers. The fact that discon-
inuation was an independent predictor of death further
ighlights the high risk of withdrawers. Similar conclusions
ere found for severe bleeding, which was dramatically
ore frequent in withdrawers versus non-withdrawers. This
s accounted for by the fact that withdrawers have factors
ommon to ischaemic risk and bleeding risk, such as age,
ex, renal failure and heart failure, and they may also have
ad a more frequent history of minor or serious bleeding, an
ndicator of bleeding risk.
The limitations of the present study are inherent to
ny subgroup analysis including patient selection bias and
se of non-randomized groups. The potential differences
n time of follow-up for events occurring after discontinua-
ion and the impact of possible open-label clopidogrel intake
fter interruption represent potential biases. Although the
ajority of events deﬁned as the primary ischaemic and
afety endpoints of the study occurred after discontin-
ation in the group of withdrawers, these events may
ave been the same as the one motivating interruption
f study drug. We also lack information on patients who
ay have interrupted other therapies or on patients who
ay have undergone bare-metal or DES implantation dur-
ng the period of follow-up. The increased risk of severe
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leeding with discontinuation is puzzling and in addition
o the hypotheses discussed above, deﬁciencies in diagnos-
ic coding may obscure the reasons why study drug was
topped in the trial. The time analyses of bleeding events
rom randomization but also from discontinuation do not
ndicate any signiﬁcant decrease in severe bleeding after
lopidogrel interruption whereas there was a clear excess
f bleeding early after clopidogrel exposition in the over-
ll population of the CHARISMA trial [29]. It is possible that
ithdrawers have a different risk proﬁle for bleeding, more
requently a prior history of bleeding before randomiza-
ion, which led them eventually to stop the study drug.
ore than 50% of severe bleeding events occurred on aspirin
lone, after the study drug discontinuation, and in par-
icular after clopidogrel interruption, further emphasizing
hat individual susceptibility to severe bleeding was present
efore randomization and is inherent to patients’ charac-
eristics rather than to exposure to the study-drug. The
ifference in time delay from randomization to interrup-
ion between patients assigned to clopidogrel versus placebo
268 versus 306) further supports this assumption and might
e explained by the early excess of moderate or severe
leeding in patients exposed to clopidogrel, as shown pre-
iously [29]. Obviously, our withdrawer population is highly
peciﬁc and would not have been suitable for a random-
zed trial evaluating interruption strategies of clopidogrel
herapy.
In conclusion, patients who permanently discontinued
he study drug (clopidogrel or placebo) in the CHARISMA
rial represent a signiﬁcant proportion of the overall popula-
ion with high-risk features and increased rates of ischaemic
nd bleeding events, as well as mortality. Patients initially
ssigned to clopidogrel had fewer ischaemic events com-
M
o
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E
Mlation who discontinued the study drug (n = 2999).
ared with those assigned to placebo and discontinuation
as not associated with any clinically detectable rebound
ffect. Assessment of the risk of discontinuation warrants
urther investigation in appropriately designed studies com-
aring maintenance to or discontinuation of clopidogrel in
igh-risk atherothrombotic patients.
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